nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
American pharmaceutical association review of literature on prescription to over-the-counter drug switches
|
Schulke, David G. |
|
1998 |
20 |
S3 |
p. C124-C133 nvt p. |
artikel |
2 |
A process for interpreting data on adverse drug events: determining optimal target levels
|
Rich, Darryl S. |
|
1998 |
20 |
S3 |
p. C59-C71 nvt p. |
artikel |
3 |
Assuring the safe use of medications: the drug approval process and improving treatment decisions
|
Pathak, DevS. |
|
1998 |
20 |
S3 |
p. C1-C3 nvt p. |
artikel |
4 |
Balancing risks versus benefits in drug therapy decisions
|
Lasagna, Louis |
|
1998 |
20 |
S3 |
p. C72-C79 nvt p. |
artikel |
5 |
Developing a uniform reporting system for preventable adverse drug events
|
Cousins, Diane D. |
|
1998 |
20 |
S3 |
p. C45-C58 nvt p. |
artikel |
6 |
Direct-to-consumer advertising: a pharmacy perspective
|
Maine, Lucinda L. |
|
1998 |
20 |
S3 |
p. C104-C110 nvt p. |
artikel |
7 |
Direct-to-consumer promotion: an industry perspective
|
Pines, Wayne L. |
|
1998 |
20 |
S3 |
p. C96-C103 nvt p. |
artikel |
8 |
Evolution of self-care with over-the-counter medications
|
Soller, R.William |
|
1998 |
20 |
S3 |
p. C134-C140 nvt p. |
artikel |
9 |
Limitations and strengths of spontaneous reports data
|
Goldman, Stephen A. |
|
1998 |
20 |
S3 |
p. C40-C44 nvt p. |
artikel |
10 |
Overview of the US Food and Drug Administration's reform legislation
|
Rheinstein, Peter H. |
|
1998 |
20 |
S3 |
p. C4-C11 nvt p. |
artikel |
11 |
Postmarketing drug surveillance: an epidemiologic approach
|
Hennessy, Sean |
|
1998 |
20 |
S3 |
p. C32-C39 nvt p. |
artikel |
12 |
Premarketing studies in the drug approval process: understanding their limitations regarding the assessment of drug safety
|
Laughren, Thomas |
|
1998 |
20 |
S3 |
p. C12-C19 nvt p. |
artikel |
13 |
Prescription to over-the-counter switch: a regulatory perspective
|
Juhl, Randy P. |
|
1998 |
20 |
S3 |
p. C111-C117 nvt p. |
artikel |
14 |
Prescription to over-the-counter switches: the physician perspective
|
Byrns, Patricia J. |
|
1998 |
20 |
S3 |
p. C118-C123 nvt p. |
artikel |
15 |
Realizing the promise of the US food and drug administration modernization act
|
Wolgemuth, RichardL. |
|
1998 |
20 |
S3 |
p. C26-C31 nvt p. |
artikel |
16 |
Regulation of prescription drug promotion: direct-to-consumer advertising
|
Baylor-Henry, Minnie |
|
1998 |
20 |
S3 |
p. C86-C95 nvt p. |
artikel |
17 |
Role of evidence-based medicine and clinical practice guidelines in treatment decisions
|
Pearson, Kay C. |
|
1998 |
20 |
S3 |
p. C80-C85 nvt p. |
artikel |
18 |
The US Food and Drug Administration Modernization Act of 1997: impact on consumers
|
Golodner, Linda F. |
|
1998 |
20 |
S3 |
p. C20-C25 nvt p. |
artikel |